Medicus Pharma Ltd (MDCX) Stock Price, Quote & News

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to M...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 610 540 7515

Website: medicuspharma.com

Address:

300 Conshohocken State Road, Suite 200, Conshohocken, United States

billsmall Nov. 15 at 12:57 AM

$MDCX Surprised we don't see Mahaffey's name under RISK FACTORS in the 10Q

0 · Reply

d_risk Nov. 14 at 9:50 PM

$MDCX - Medicus Pharma Ltd. - 10Q - Updated Risk Factors MDCX flags risks around integrating Antev and the successful development of Teverelix as key uncertainties in its latest 10-Q. #Pharmaceuticals #MarketUncertainty #ClinicalRisk #DrugDevelopment #MergersIntegration 🟢 Added 🟠 Removed https://d-risk.ai/MDCX/10-Q/2025-11-14

0 · Reply

BillionerOfKing Nov. 14 at 3:30 PM

$MDCX Current Stock Price: $2.20 No options data available.

0 · Reply

JackRyan55 Nov. 14 at 5:12 AM

$MDCX you can't sell high if you don't buy low.

0 · Reply

kilo1212 Nov. 13 at 7:25 PM

$MDCX i aint no basher. Patrick mahaffey should be in prison. So why did this company hire him. Its not for his knowledge in bio tech. So google Patrick mahaffey and you find out over last ten years how this man has destroyed his own company clvs before. He had to pay 20 million of stock holders money for lying about his Drug phase results. Just go look everything up about this man. Other than that i hope you all make money in this stock. Im not a shareholder after i found out about this guy is part of this company. The MF should be in prison.

2 · Reply

bullrider19 Nov. 13 at 3:11 PM

$MDCX the squeeze pop drop $2.20

0 · Reply

bullrider19 Nov. 13 at 1:52 PM

$MDCX excellent flippppping gap .26-.44 ill take it all-day #7660 $$$$$$$$$ BULL in my pocket bull bear who-cares GAP trade

0 · Reply

JarvisFlow Nov. 13 at 1:11 PM

D. Boral Capital updates rating for Medicus Pharma ( $MDCX ) to Buy, target set at 27.

0 · Reply

makedatbread88 Nov. 13 at 12:37 PM

$MDCX low floater with huge news adding!

0 · Reply

jdlman Nov. 13 at 12:34 PM

$MDCX good news

0 · Reply

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 13, 2025, 7:30 AM EST - 1 day ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 29, 2025, 7:30 AM EDT - 16 days ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 16 days ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 22, 2025, 7:30 AM EDT - 23 days ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 14, 2025, 8:07 AM EDT - 4 weeks ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 13, 2025, 7:30 AM EDT - 4 weeks ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 7, 2025, 7:30 AM EDT - 5 weeks ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Sep 29, 2025, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 24, 2025, 9:26 AM EDT - 7 weeks ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 7:30 AM EDT - 7 weeks ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 18, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 8, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Aug 21, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 4, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Jul 23, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 21, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 8, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 4, 2025, 9:49 AM EDT - 4 months ago

Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment

Jun 30, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 23, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 12, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 9, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Jun 2, 2025, 1:40 PM EDT - 5 months ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

May 29, 2025, 8:30 PM EDT - 6 months ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 22, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 12, 2025, 2:20 PM EDT - 6 months ago

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

Apr 28, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Apr 21, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Mar 10, 2025, 4:05 PM EDT - 8 months ago

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Mar 6, 2025, 8:30 PM EST - 9 months ago

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Mar 6, 2025, 7:30 AM EST - 9 months ago

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 27, 2025, 7:30 AM EST - 9 months ago

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 11, 2025, 7:41 AM EST - 9 months ago

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Dec 12, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Dec 2, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Nov 18, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Nov 15, 2024, 4:47 PM EST - 1 year ago

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Nov 13, 2024, 6:45 PM EST - 1 year ago

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

billsmall Nov. 15 at 12:57 AM

$MDCX Surprised we don't see Mahaffey's name under RISK FACTORS in the 10Q

0 · Reply

d_risk Nov. 14 at 9:50 PM

0 · Reply

BillionerOfKing Nov. 14 at 3:30 PM

$MDCX Current Stock Price: $2.20 No options data available.

0 · Reply

JackRyan55 Nov. 14 at 5:12 AM

$MDCX you can't sell high if you don't buy low.

0 · Reply

kilo1212 Nov. 13 at 7:25 PM

2 · Reply

bullrider19 Nov. 13 at 3:11 PM

$MDCX the squeeze pop drop $2.20

0 · Reply

bullrider19 Nov. 13 at 1:52 PM

$MDCX excellent flippppping gap .26-.44 ill take it all-day #7660 $$$$$$$$$ BULL in my pocket bull bear who-cares GAP trade

0 · Reply

JarvisFlow Nov. 13 at 1:11 PM

D. Boral Capital updates rating for Medicus Pharma ( $MDCX ) to Buy, target set at 27.

0 · Reply

makedatbread88 Nov. 13 at 12:37 PM

$MDCX low floater with huge news adding!

0 · Reply

jdlman Nov. 13 at 12:34 PM

$MDCX good news

0 · Reply

TradesWolf Nov. 13 at 12:31 PM

$MDCX great news 🗞️

0 · Reply

Stock_Catcher Nov. 13 at 12:31 PM

$MDCX Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

0 · Reply

razorsedge4343 Nov. 11 at 8:55 PM

$MDCX This thing didn't get the memo that biotech is flying today...

0 · Reply

2TrustHim Nov. 11 at 1:09 PM

$MDCX https://youtu.be/Tx3jKESzygg?si=MVVDRXG97xnWFhZr

0 · Reply

2TrustHim Nov. 10 at 6:08 PM

$MDCX Update For Newbies!!! https://www.b-tv.com/post/medicus-pharma-reshaping-the-standard-of-healthcare-with-novel-therapies

0 · Reply

2TrustHim Nov. 7 at 5:21 PM

$MDCX The Company Explaining How They Kind Of Finance The In Between Before A Partner Or Buyout Opportunity Shows Up Should Be Interesting!!!

0 · Reply

MaryAlexander707 Nov. 7 at 4:42 PM

$MDCX posts light upward movement. AITX delivers strong client satisfaction with new ROSA installations and SARA-enabled automation.

0 · Reply

2TrustHim Nov. 7 at 3:28 PM

$MDCX Hoping The Weekend Showcase Get's Some Interested Buyers On Monday Etc.

0 · Reply

2TrustHim Nov. 7 at 1:51 PM

$MDCX FOX Business Featuring MEDICUS November 8th 5:00pm

0 · Reply

kilo1212 Nov. 5 at 1:22 PM

$MDCX my last warning about Patrick Mahaffey.

1 · Reply

billsmall Nov. 4 at 6:27 PM

$MDCX Until you get rid of this guy this is your fate.

0 · Reply

__SquuezedChronometer_ Nov. 2 at 10:55 AM

Next major retail squeeze candidate right here $USBC $MDCX $NITO $BIAF 3

0 · Reply

Market Cap	40.26M
Revenue (ttm)	0.00
Net Income (ttm)	-11.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	121,500
Avg Vol	346,804
Day's Range	N/A - N/A
Shares Out	17.82M
Stochastic %K	14%
Beta	N/A
Analysts	Strong Sell
Price Target	$22.33